1. Does Managed Care Fuel Pharmaceutical Industry Growth?

   • Michael D. Murray
   • Frank W. Deardorff

   Current Opinion 17 September 2012 Pages: 341 - 348

2. Mega-Mergers in the Pharmaceutical Industry

   • Alain Li Wan Po

   Current Opinion 17 September 2012 Pages: 349 - 355

3. The Problem of Protocol Driven Costs in Pharmacoeconomic Analysis

   • Douglas Coyle
   • Karen M. Lee

   Leading Article 17 September 2012 Pages: 357 - 363

4. A Review of the Economics of the Prevention and Control of Rabies

   • Martin I. Meltzer
   • Charles E. Rupprecht

   Review Article 17 September 2012 Pages: 365 - 383

5. Economic Impact of Aminoglycoside Toxicity and its Prevention Through Therapeutic Drug Monitoring

   • Richard L. Slaughter
   • Diane M. Cappelletty

   Review Article 17 September 2012 Pages: 385 - 394

6. The Burden of Illness of Hypopituitary Adults with Growth Hormone Deficiency

   • Leona Hakkaart-van Roijen
   • Albert Beckers
   • Frans F. H. Rutten

   Original Research Article 17 September 2012 Pages: 395 - 403

7. A Method to Select an Instrument for Measurement of HR-QOL for Cross-Cultural Adaptation Applied to Dermatology

   • Adolfo Ga de Tiedra
   • Joan Mercadal
   • Rafael Lozano

   Original Research Article 17 September 2012 Pages: 405 - 422

8. Threshold Analysis of Helicobacter pylori Therapy

   • Amnon Sonnenberg

   Original Research Article 17 September 2012 Pages: 423 - 432

9. Cost Effectiveness of Fluvoxamine in the Treatment of Recurrent Depression in France

   • Mark Nuijten
   • Lionel Hadjadjeba
   • John van den Berg

   Original Research Article 17 September 2012 Pages: 433 - 445

10. Docetaxel

    • Harriet M. Lamb
    • Lynda R. Wiseman

    Adis Pharmacoeconomic Drug Evaluation 17 September 2012 Pages: 447 - 459